Phase 2 Pancreatic Cancer Trial, Recruiting (NCT06850623)

Phase 2 Pancreatic Cancer Trial, Recruiting NCT06850623 Sponsor: EXACT Therapeutics AS Condition: Pancreatic Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06850623 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pancreatic Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Your doctors have determined that surgery is not currently a suitable option for you, and scans and biopsy results show that your pancreatic cancer cannot be removed by surgery or is on the borderline of being removable.
Your doctor believes you are well enough to receive a specific chemotherapy combination called mFOLFIRINOX.

Who may not be able to join:

You have already received any cancer treatment for your pancreatic cancer, such as chemotherapy, surgery, or radiation therapy (note: procedures to relieve a blocked bile duct or to reroute digestion for comfort are still allowed).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06850623

Sponsor: EXACT Therapeutics AS

Phase: Phase 2

Status: Recruiting

Condition: Pancreatic Cancer

More information: https://clinicaltrials.gov/study/NCT06850623

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Your doctors have determined that surgery is not currently a suitable option for you, and scans and biopsy results show that your pancreatic cancer cannot be removed by surgery or is on the borderline of being removable.
Your doctor believes you are well enough to receive a specific chemotherapy combination called mFOLFIRINOX.

Who may not be able to join:

You have already received any cancer treatment for your pancreatic cancer, such as chemotherapy, surgery, or radiation therapy (note: procedures to relieve a blocked bile duct or to reroute digestion for comfort are still allowed).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

EXACT Therapeutics AS

Registry

ClinicalTrials.gov

Start date

19 June 2025

Est. completion

15 December 2026

Where this trial is recruiting

🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

ORR (Overall response rate), defined as the number of participants with measurable disease at baseline who have a confirmed Complete Response or confirmed Partial Response according to RECIST Version 1.1.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov